Jagsonpal Pharmaceuticals reported consolidated revenue of Rs 96 crore for Q2 FY27, marking a 29% growth. The company, which recently completed acquisitions of Aequitas and Group Pharma Wellness, aims to reach Rs 500 crore in annual revenue by FY 2028 through organic expansion. Investors should watch for margin stabilization as the firm integrates lower-margin hospital businesses.
Jagsonpal Pharmaceuticals Posts Rs 96 Crore Revenue in Q2 FY27
Consolidated revenue stood at Rs 96 crore with a 29% growth; standalone revenue reached Rs 81 crore.
Reader Takeaway: Revenue growth is accelerating through acquisitions, but investors must monitor potential margin dilution from new institutional channels.
What just happened
Jagsonpal Pharmaceuticals has released its financial results for Q2 FY27, marking its first quarter of reporting consolidated figures. The company posted consolidated revenue of Rs 96 crore, up 29%, while standalone revenue grew 9.3% to Rs 81 crore. EBITDA margins for the standalone business held steady at 22.7%, while the consolidated margin settled at 19.3%.
Strategic Growth and Acquisitions
The company is aggressively scaling through two recent acquisitions. It bought Aequitas in July 2026 to enter the hospital and institutional segment and added the Group Pharma Wellness portfolio in October 2026 to strengthen its presence in the hematinics and respiratory sectors across six states. The company sits on a healthy cash balance of over Rs 135 crore.
Management Commentary and Guidance
Management remains committed to an ambitious goal of achieving Rs 500 crore in annual revenue by FY 2028 through organic growth. For the upcoming Q3 FY27, the company anticipates surpassing Rs 100 crore in quarterly revenue. Despite the entry into lower-margin hospital segments, management aims to keep consolidated EBITDA margins above 22% over time, aided by a 10% improvement in Medical Representative (MR) productivity.
Risks to watch
Integration risks remain the primary concern as the newly acquired assets are still in the early stages of onboarding. Furthermore, the hospital and institutional business operates at lower margins than the core branded portfolio, which may create short-term volatility in overall consolidated margins. Management also noted potential discrepancies between internal data and external market research reports due to sampling variations.
What to track next
Investors should monitor the quarterly progression of the newly acquired businesses and whether the company can maintain its projected EBITDA-accretive growth while scaling toward its long-term revenue targets.